Recent Updates
Recently added Catalysts
CHE

David P. William s (513) 762-6901  Chemed Reports Third-Quarter 2019 Results  CINCINNATI

Key Takeaway: CONTACT: David P. Williams Chemed Reports Third-Quarter 2019 Results CINCINNATI, October 29, 2019 Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation

Full Press Release Details

CONTACT: David P. Williams
Chemed Reports Third-Quarter 2019 Results
CINCINNATI, October 29, 2019 Chemed Corporation (Chemed) (NYSE: CHE), which operates VITAS Healthcare Corporation (VITAS), one of the nation's largest providers of end-of-life care, and Roto-Rooter, the nation's largest commercial and residential plumbing and drain cleaning services provider, reported financial results for its third quarter ended September 30, 2019, versus the comparable prior-year period, as follows:
Consolidated operating results:
VITAS segment operating results:
Roto-Rooter segment operating results:
VITAS net revenue was $322 million in the third quarter of 2019, which is an increase of 6.6%, when compared to the prior-year period. This revenue increase is comprised primarily of a geographically weighted average Medicare reimbursement rate increase of approximately 0.5%, a 6.3% increase in days-of-care and a reduction in the Medicare Cap billing limitation that increased revenue 0.2%. This growth was partially offset by acuity mix shift, fluctuations in net room and board and contractual adjustments, the combination of which negatively impacted revenue growth approximately 0.4%, when compared to the prior-year period.
In the third quarter of 2019, VITAS accrued $1.3 million in Medicare Cap billing limitations. This compares favorably to the prior-year Medicare Cap billing limitation of $2.0 million. At September 30, 2019, VITAS had 30 Medicare provider numbers, three of which have an estimated fiscal 2019 Medicare Cap billing limitation liability of approximately $9.6 million.
Of VITAS' 30 Medicare provider numbers, 23 provider numbers have a Medicare Cap cushion of 10% or greater, one provider number has a cap cushion between 5% and 10%, three provider numbers have a cap cushion between 0% and 5%, and three provider numbers have a fiscal 2019 Medicare Cap billing limitation.
Average revenue per patient per day in the quarter was $188.02, which is 0.4% above the prior-year period. Reimbursement for routine home care and high acuity care averaged $164.39 and $755.38, respectively. During the quarter, high acuity days-of-care were 4.0% of total days of care, 7-basis points less than the prior-year quarter.
The third quarter of 2019 gross margin, excluding Medicare Cap, was 23.4%, which is a 9-basis point margin improvement when compared to the third quarter of 2018.
Selling, general and administrative expense was $22.0 million in the third quarter of 2019, which is an increase of 7.7% compared to the prior-year quarter. Adjusted EBITDA, excluding Medicare Cap, totaled $54.3 million in the quarter, an increase of 6.7%. Adjusted EBITDA margin, excluding Medicare Cap, was 16.8% in the quarter, which is a 5-basis point margin improvement when compared to the prior-year period.
Roto-Rooter generated quarterly revenue of $159 million for the third quarter of 2019, an increase of $16.5 million, or 11.6%, over the prior-year quarter. Revenue from the water restoration service segment totaled $25.7 million, an increase of 3.0%, when compared to the prior-year quarter. Approximately 90% of the water restoration revenue is generated from residential customers and the remaining 10% is generated from commercial accounts.
Commercial drain cleaning revenue increased 16.5%, commercial plumbing and excavation increased 24.9%, and commercial water restoration increased 3.1%. Overall, commercial revenue increased 19.3%.
Residential drain cleaning increased 9.8%, plumbing and excavation increased 7.0%, and residential water restoration increased 2.9%. Aggregate residential sales increased 6.5%.
Roto-Rooter's gross margin in the quarter was 49.2%, a slight increase when compared to the third quarter of 2018. Adjusted EBITDA in the third quarter of 2019 totaled $39.8 million, an increase of 17.0%. The Adjusted EBITDA margin in the quarter was 25.0% which is a 116-basis point margin expansion over the prior year.
As of September 30, 2019, Chemed had total cash and cash equivalents of $9 million and debt of $130 million.
In June 2018, Chemed entered into a five-year Amended and Restated Credit Agreement that consists of a $450 million revolving credit facility. The interest rate on this facility has a floating rate that is currently LIBOR plus 100-basis points. At September 30, 2019, the Company had approximately $282 million of undrawn borrowing capacity under this credit agreement.
The Company did not purchase any shares during the third quarter of 2019. As of September 30, 2019, there was approximately $125 million of remaining share repurchase authorization under this share repurchase program.
Chemed restarted its share repurchase program in 2007. Since that time Chemed has repurchased over 14 million shares, aggregating approximately $1.2 billion at an average share cost of $84.76. Including dividends over this period, Chemed has returned approximately $1.4 billion to shareholders.
Chemed will host a conference call and webcast at 10 a.m., ET, on Wednesday, October 30, 2019, to discuss the Company's quarterly results and to provide an update on its business. The dial-in number for the conference call is (844) 743-2500 for U.S. and Canadian participants and +1 (661) 378-9533 for international participants. The Conference ID is 5229315. A live webcast of the call can be accessed on Chemed's website at www.chemed.com by clicking on Investor Relations Home.
A taped replay of the conference call will be available beginning approximately 24 hours after the call's conclusion. It can be accessed by dialing (855) 859-2056 for U.S. and Canadian callers and +1 (404) 537-3406 for international callers and will be available for one week following the live call. The replay Conference ID is 5229315. An archived webcast will also be available at www.chemed.com.
Chemed Corporation operates in the healthcare field through its VITAS Healthcare Corporation subsidiary. VITAS provides daily hospice services to approximately 19,000 patients with severe, life-limiting illnesses. This type of care is focused on making the terminally ill patient's final days as comfortable and pain-free as possible.
Chemed operates in the residential and commercial plumbing and drain cleaning industry under the brand name Roto-Rooter. Roto-Rooter provides plumbing, drain cleaning, and water cleanup services through company-owned branches, independent contractors and franchisees in the United States and Canada. Roto-Rooter also has licensed master franchisees in the republics of Indonesia and Singapore, and the Philippines.
This press release contains information about Chemed's EBITDA, Adjusted EBITDA and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understanding Chemed's financial performance. In reporting its operating results, Chemed provides EBITDA, Adjusted EBITDA and Adjusted Diluted EPS measures to help investors and others evaluate the Company's operating results, compare its operating performance with that of similar companies that have different capital structures and evaluate its ability to meet its future debt service, capital expenditures and working
capital requirements. Chemed's management similarly uses EBITDA, Adjusted EBITDA and Adjusted Diluted EPS to assist it in evaluating the performance of the Company across fiscal periods and in assessing how its performance compares to its peer companies. These measures also help Chemed's management to estimate the resources required to meet Chemed's future financial obligations and expenditures. Chemed's EBITDA, Adjusted EBITDA and Adjusted Diluted EPS should not be considered in isolation or as a substitute for comparable measures calculated and presented in accordance with GAAP. We calculated Adjusted EBITDA Margin by dividing Adjusted EBITDA by service revenue and sales. A reconciliation of Chemed's net income to its EBITDA, Adjusted EBITDA and Adjusted Diluted EPS is presented in the tables following the text of this press release.
Forward-Looking Statements
Certain statements contained in this press release and the accompanying tables are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "hope," "anticipate," "plan" and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Chemed does not undertake and specifically disclaims any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These statements are based on current expectations and assumptions and involve various risks and uncertainties, which could cause Chemed's actual results to differ from those expressed in such forward-looking statements.
These risks and uncertainties arise from, among other things, possible changes in regulations governing the hospice care or plumbing and drain cleaning industries; periodic changes in reimbursement levels and procedures under Medicare and Medicaid programs; difficulties predicting patient length of stay and estimating potential Medicare reimbursement obligations; challenges inherent in Chemed's growth strategy; the current shortage of qualified nurses, other healthcare professionals and licensed plumbing and drain cleaning technicians; Chemed's dependence on patient referral sources; and other factors detailed under the caption "Description of Business by Segment" or "Risk Factors" in Chemed's most recent report on form 10-Q or 10-K and its other filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on such forward-looking statements and there are no assurances that the matters contained in such statements will be achieved.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)(unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2019 2018 2019 2018
Service revenues and sales 480,613 $ 444,151 $ 1,416,231 $ 1,325,140
Cost of services provided and goods sold 328,183 305,312 973,771 915,589
Selling, general and administrative expenses (aa) 76,836 67,177 222,421 204,474
Depreciation 10,147 9,657 29,744 28,642
Amortization 441 35 1,366 96
Other operating expenses 78 257 9,001 88
Total costs and expenses 415,685 382,438 1,236,303 1,148,889
Income from operations 64,928 61,713 179,928 176,251
Interest expense (1,041) (1,082) (3,402) (3,813)
Other income--net (bb) 3,036 2,300 5,488 4,356
Income before income taxes 66,923 62,931 182,014 176,794
Income taxes (7,976) (11,682) (27,671) (25,578)
Net income $ 58,947 $ 51,249 $ 154,343 $ 151,216
Earnings Per Share
Net income $ 3.69 $ 3.19 $ 9.68 $ 9.41
Average number of shares outstanding 15,970 16,074 15,952 16,070
Diluted Earnings Per Share
Net income $ 3.56 $ 3.06 $ 9.35 $ 8.98
Average number of shares outstanding 16,555 16,772 16,514 16,830
(aa) Selling, general and administrative ("SG&A") expenses comprise (in thousands):
Three Months Ended September 30, Nine Months Ended September 30,
2019 2018 2019 2018
SG&A expenses before long-term incentive compensation and the impact of market value adjustments related to deferred compensation plans $ 72,273 $ 63,754 $ 212,775 $ 196,271
Market value adjustments related to deferred compensation trusts 2,886 2,189 5,094 3,827
Long-term incentive compensation 1,677 1,234 4,552 4,376
Total SG&A expenses $ 76,836 $ 67,177 $ 222,421 $ 204,474
(bb) Other income--net comprises (in thousands):
Three Months Ended September 30, Nine Months Ended September 30,
2019 2018 2019 2018
Market value adjustments related to deferred compensation trusts $ 2,886 $ 2,189 $ 5,094 $ 3,827
Interest income 173 111 387 529
Other (23) - 7 -
Total other income--net $ 3,036 $ 2,300 $ 5,488 $ 4,356
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED BALANCE SHEETS
(in thousands, except per share data)(unaudited)
September 30,
2019 2018
Assets
Current assets
Cash and cash equivalents $ 9,066 $ 67,459
Accounts receivable less allowances 114,480 108,999
Inventories 7,354 5,763
Prepaid income taxes 10,745 6,039
Prepaid expenses 26,150 17,610
Total current assets 167,795 205,870
Investments of deferred compensation plans held in trust 73,714 70,237
Properties and equipment, at cost less accumulated depreciation 172,932 154,434
Lease right of use asset 103,286 -
Identifiable intangible assets less accumulated amortization 129,276 56,649
Goodwill 576,600 483,281
Other assets 8,982 8,653
Total Assets $ 1,232,585 $ 979,124
Liabilities
Current liabilities
Accounts payable $ 44,027 $ 36,977
Accrued insurance 47,726 43,503
Accrued compensation 75,208 70,687
Accrued legal 7,283 1,423
Short-term lease liability 33,761 -
Other current liabilities 43,496 27,608
Total current liabilities 251,501 180,198
Deferred income taxes 15,512 15,293
Long-term debt 130,000 130,000
Deferred compensation liabilities 73,335 68,492
Long-term lease liability 82,012 -
Other liabilities 7,845 16,988
Total Liabilities 560,205 410,971
Stockholders' Equity
Capital stock 35,738 35,211
Paid-in capital 841,837 755,263
Retained earnings 1,365,303 1,175,949
Treasury stock, at cost (1,572,844) (1,400,577)
Deferred compensation payable in Company stock 2,346 2,307
Total Stockholders' Equity 672,380 568,153
Total Liabilities and Stockholders' Equity $ 1,232,585 $ 979,124
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)(unaudited)
Nine Months Ended September 30,
2019 2018
Cash Flows from Operating Activities
Net income $ 154,343 $ 151,216
Adjustments to reconcile net income to net cash provided
by operating activities:
Depreciation and amortization 31,110 28,738
Stock option expense 10,729 9,360
Benefit for deferred income taxes (6,085) (1,344)
Litigation settlement 6,000 -
Noncash long-term incentive compensation 4,184 4,176
Asset impairment loss 2,266 -
Noncash directors' compensation 767 766
Amortization of debt issuance costs 229 361
Amortization of restricted stock awards - 446
Changes in operating assets and liabilities, excluding
amounts acquired in business combinations:
Decrease in accounts receivable 10,558 4,637
Increase in inventories (1,649) (429)
Increase in prepaid expenses (6,836) (1,518)
Increase in accounts payable and
other current liabilities 28,622 12,182
Change in current income taxes (81) 23,858
Net change in lease assets and liabilities 1,311 -
Increase in other assets (8,145) (9,441)
Increase in other liabilities 9,045 7,190
Other sources 1,277 410
Net cash provided by operating activities 237,645 230,608
Cash Flows from Investing Activities
Business combinations, net of cash acquired (138,010) (12,875)
Capital expenditures (39,753) (36,554)
Other sources 101 480
Net cash used by investing activities (177,662) (48,949)
Cash Flows from Financing Activities
Proceeds from revolving line of credit 400,700 428,150
Payments on revolving line of credit (359,900) (324,350)
Purchases of treasury stock (71,926) (121,976)
Capital stock surrendered to pay taxes on stock-based compensation (26,108) (24,763)
Proceeds from exercise of stock options 23,383 23,079
Dividends paid (14,657) (13,850)
Change in cash overdrafts payable (7,535) (15,307)
Payments on other long-term debt - (75,000)
Debt issuance costs - (985)
Other sources/(uses) 295 (319)
Net cash used by financing activities (55,748) (125,321)
Increase in Cash and Cash Equivalents 4,235 56,338
Cash and cash equivalents at beginning of year 4,831 11,121
Cash and cash equivalents at end of year $ 9,066 $ 67,459
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018
(in thousands)(unaudited)
Chemed
VITAS Roto-Rooter Corporate Consolidated
2019
Service revenues and sales (a) $ 321,748 $ 158,865 $ - $ 480,613
Cost of services provided and goods sold 247,551 80,632 - 328,183
Selling, general and administrative expenses (a) 21,965 41,758 13,113 76,836
Depreciation 5,105 5,003 39 10,147
Amortization 18 423 - 441
Other operating expense/(income) 97 (19) - 78
Total costs and expenses 274,736 127,797 13,152 415,685
Income/(loss) from operations 47,012 31,068 (13,152) 64,928
Interest expense (48) (80) (913) (1,041)
Intercompany interest income/(expense) 4,618 2,234 (6,852) -
Other income net 121 31 2,884 3,036
Income/(loss) before income taxes 51,703 33,253 (18,033) 66,923
Income taxes (a) (11,930) (7,113) 11,067 (7,976)
Net income/(loss) $ 39,773 $ 26,140 $ (6,966) $ 58,947
2018
Service revenues and sales (b) $ 301,764 $ 142,387 $ - $ 444,151
Cost of services provided and goods sold 233,006 72,306 - 305,312
Selling, general and administrative expenses (b) 20,394 36,112 10,671 67,177
Depreciation 4,905 4,712 40 9,657
Amortization - 35 - 35
Other operating expense 100 157 - 257
Total costs and expenses 258,405 113,322 10,711 382,438
Income/(loss) from operations 43,359 29,065 (10,711) 61,713
Interest expense (49) (71) (962) (1,082)
Intercompany interest income/(expense) 3,306 1,814 (5,120) -
Other income net 89 22 2,189 2,300
Income/(loss) before income taxes 46,705 30,830 (14,604) 62,931
Income taxes (b) (10,784) (6,267) 5,369 (11,682)
Net income/(loss) $ 35,921 $ 24,563 $ (9,235) $ 51,249
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING STATEMENTS OF INCOME
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018
(in thousands)(unaudited)
Chemed
VITAS Roto-Rooter Corporate Consolidated
2019
Service revenues and sales (a) $ 941,279 $ 474,952 $ - $ 1,416,231
Cost of services provided and goods sold 728,397 245,374 - 973,771
Selling, general and administrative expenses (a) 65,182 120,736 36,503 222,421
Depreciation 14,644 14,983 117 29,744
Amortization 53 1,313 - 1,366
Other operating expense (a) 6,521 214 2,266 9,001
Total costs and expenses 814,797 382,620 38,886 1,236,303
Income/(loss) from operations 126,482 92,332 (38,886) 179,928
Interest expense (150) (273) (2,979) (3,402)
Intercompany interest income/(expense) 13,395 6,609 (20,004) -
Other income net 309 86 5,093 5,488
Income/(loss) before income taxes 140,036 98,754 (56,776) 182,014
Income taxes (a) (33,636) (22,452) 28,417 (27,671)
Net income/(loss) $ 106,400 $ 76,302 $ (28,359) $ 154,343
2018
Service revenues and sales (b) $ 890,577 $ 434,563 $ - $ 1,325,140
Cost of services provided and goods sold 693,335 222,254 - 915,589
Selling, general and administrative expenses (b) 61,606 108,120 34,748 204,474
Depreciation 14,753 13,782 107 28,642
Amortization - 96 - 96
Other operating expense (b) 16 72 - 88
Total costs and expenses 769,710 344,324 34,855 1,148,889
Income/(loss) from operations 120,867 90,239 (34,855) 176,251
Interest expense (153) (255) (3,405) (3,813)
Intercompany interest income/(expense) 9,524 5,231 (14,755) -
Other income net 469 60 3,827 4,356
Income/(loss) before income taxes 130,707 95,275 (49,188) 176,794
Income taxes (b) (30,987) (22,476) 27,885 (25,578)
Net income/(loss) $ 99,720 $ 72,799 $ (21,303) $ 151,216
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018
(in thousands)(unaudited)
Chemed
VITAS Roto-Rooter Corporate Consolidated
2019
Net income/(loss) $ 39,773 $ 26,140 $ (6,966) $ 58,947
Add/(deduct):
Interest expense 48 80 913 1,041
Income taxes 11,930 7,113 (11,067) 7,976
Depreciation 5,105 5,003 39 10,147
Amortization 18 423 - 441
EBITDA 56,874 38,759 (17,081) 78,552
Add/(deduct):
Intercompany interest expense/(income) (4,618) (2,234) 6,852 -
Interest income (139) (34) - (173)
Acquisition expense - 3,281 - 3,281
Stock option expense - - 2,711 2,711
Long-term incentive compensation - - 1,677 1,677
Medicare cap sequestration adjustment 859 - - 859
Adjusted EBITDA $ 52,976 $ 39,772 $ (5,841) $ 86,907
2018
Net income/(loss) $ 35,921 $ 24,563 $ (9,235) $ 51,249
Add/(deduct):
Interest expense 49 71 962 1,082
Income taxes 10,784 6,267 (5,369) 11,682
Depreciation 4,905 4,712 40 9,657
Amortization - 35 - 35
EBITDA 51,659 35,648 (13,602) 73,705
Add/(deduct):
Intercompany interest expense/(income) (3,306) (1,814) 5,120 -
Interest income (88) (23) - (111)
Medicare cap sequestration adjustment 503 - - 503
Acquisition expense 177 177 - 354
Stock option expense - - 2,055 2,055
Long-term incentive compensation - - 1,234 1,234
Adjusted EBITDA $ 48,945 $ 33,988 $ (5,193) $ 77,740
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
CONSOLIDATING SUMMARIES OF EBITDA
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018
(in thousands)(unaudited)
Chemed
VITAS Roto-Rooter Corporate Consolidated
2019
Net income/(loss) $ 106,400 $ 76,302 $ (28,359) $ 154,343
Add/(deduct):
Interest expense 150 273 2,979 3,402
Income taxes 33,636 22,452 (28,417) 27,671
Depreciation 14,644 14,983 117 29,744
Amortization 53 1,313 - 1,366
EBITDA 154,883 115,323 (53,680) 216,526
Add/(deduct):
Intercompany interest expense/(income) (13,395) (6,609) 20,004 -
Interest income (296) (91) - (387)
Stock option expense - - 10,729 10,729
Litigation settlement 6,000 - - 6,000
Long-term incentive compensation - - 4,552 4,552
Acquisition Expense - 3,377 120 3,497
Medicare cap sequestration adjustment 3,063 - - 3,063
Impairment loss on transportation equipment - - 2,266 2,266
Non cash ASC 842 expenses/(benefit) 656 55 (163) 548
Adjusted EBITDA $ 150,911 $ 112,055 $ (16,172) $ 246,794
2018
Net income/(loss) $ 99,720 $ 72,799 $ (21,303) $ 151,216
Add/(deduct):
Interest expense 153 255 3,405 3,813
Income taxes 30,987 22,476 (27,885) 25,578
Depreciation 14,753 13,782 107 28,642
Amortization - 96 - 96
EBITDA 145,613 109,408 (45,676) 209,345
Add/(deduct):
Intercompany interest expense/(income) (9,524) (5,231) 14,755 -
Interest income (468) (60) - (528)
Stock option expense - - 9,360 9,360
Long-term incentive compensation - - 4,376 4,376
Medicare cap sequestration adjustment 1,040 - - 1,040
Amortization of stock awards 107 100 239 446
Acquisition expense 177 177 - 354
Litigation settlement (204) - - (204)
Adjusted EBITDA $ 136,741 $ 104,394 $ (16,946) $ 224,189
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
RECONCILIATION OF ADJUSTED NET INCOME
(in thousands, except per share data)(unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
2019 2018 2019 2018
Net income as reported $ 58,947 $ 51,249 $ 154,343 $ 151,216
Add/(deduct) pre-tax cost of:
Stock option expense 2,711 2,055 10,729 9,360
Litigation settlement - - 6,000 (204)
Long-term incentive compensation 1,677 1,234 4,552 4,376
Acquisition expense 3,281 354 3,497 354
Medicare cap sequestration adjustments 859 503 3,063 1,040
Impairment loss on transportation equipment - - 2,266 -
Amortization of acquired and cancelled franchise agreements 331 - 1,103 -
Non cash ASC 842 expenses - - 548 -
Add/(deduct) tax impacts:
Tax impact of the above pre-tax adjustments (1) (1,801) (821) (6,761) (3,059)
Excess tax benefits on stock compensation (8,792) (3,118) (18,737) (18,618)
Adjusted net income $ 57,213 $ 51,456 $ 160,603 $ 144,465
Diluted Earnings Per Share As Reported
Net income $ 3.56 $ 3.06 $ 9.35 $ 8.98
Average number of shares outstanding 16,555 16,772 16,514 16,830
Adjusted Diluted Earnings Per Share
Adjusted net income $ 3.46 $ 3.07 $ 9.73 $ 8.58
Average number of shares outstanding 16,555 16,772 16,514 16,830
(1) The tax impact of pre-tax adjustments was calculated using the effective tax rate of the operating unit for which each adjustment is associated.
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
OPERATING STATISTICS FOR VITAS SEGMENT
(unaudited)
Three Months Ended September 30, Nine Months Ended September 30,
OPERATING STATISTICS 2019 2018 2019 2018
Net revenue ($000) (c)
Homecare $ 274,746 $ 257,134 $ 800,059 $ 748,546
Inpatient 23,599 19,617 69,063 61,803
Continuous care 29,446 30,385 92,476 91,664
Other 2,356 2,104 6,598 5,844
Subtotal $ 330,147 $ 309,240 $ 968,196 $ 907,857
Room and board, net (2,846) (2,569) (8,098) (7,863)
Contractual allowances (4,236) (2,957) (10,904) (8,749)
Medicare cap allowance (1,317) (1,950) (7,915) (668)
Net Revenue $ 321,748 $ 301,764 $ 941,279 $ 890,577
Net revenue as a percent of total before Medicare cap allowance
Homecare 83.2 % 83.2 % 82.6 % 82.5 %
Inpatient 7.1 6.3 7.1 6.8
Continuous care 8.9 9.8 9.6 10.1
Other 0.8 0.7 0.7 0.6
Subtotal 100.0 100.0 100.0 100.0
Room and board, net (0.9) (0.8) (0.8) (0.9)
Contractual allowances (1.3) (1.0) (1.2) (1.0)
Medicare cap allowance (0.4) (0.6) (0.8) (0.1)
Net Revenue 97.4 % 97.6 % 97.2 % 98.0 %
Average daily census ("ADC") (days)
Homecare 14,799 13,791 14,510 13,515
Nursing home 3,483 3,402 3,374 3,298
Routine homecare 18,282 17,193 17,884 16,813
Inpatient 373 313 363 328
Continuous care 431 451 460 466
Total 19,086 17,957 18,707 17,607
Total Admissions 17,131 16,403 52,380 51,540
Total Discharges 16,915 16,171 51,274 50,234
Average length of stay (days) 92.6 90.0 91.6 89.0
Median length of stay (days) 17.0 18.0 16.0 16.0
ADC by major diagnosis
Cerebro 35.7 % 36.2 % 35.9 % 36.5 %
Neurological 20.7 18.8 20.4 18.7
Cancer 12.9 13.8 12.9 13.8
Cardio 16.6 16.4 16.7 16.4
Respiratory 8.1 8.1 8.1 8.1
Other 6.0 6.7 6.0 6.5
Total 100.0 % 100.0 % 100.0 % 100.0 %
Admissions by major diagnosis
Cerebro 21.1 % 21.1 % 20.8 % 21.9 %
Neurological 12.7 11.6 12.6 11.3
Cancer 30.5 31.5 29.2 30.0
Cardio 14.8 14.7 15.7 15.3
Respiratory 10.2 10.3 11.3 11.0
Other 10.7 10.8 10.4 10.5
Total 100.0 % 100.0 % 100.0 % 100.0 %
Estimated uncollectible accounts as a percent of revenues 1.3 % 1.0 % 1.1 % 1.0 %
Accounts receivable --
Days of revenue outstanding- excluding unapplied Medicare payments 32.7 36.0 n.a. n.a.
Days of revenue outstanding- including unapplied Medicare payments 21.0 22.8 n.a. n.a.
The "Footnotes to Financial Statements" are integral parts of this financial information.
CHEMED CORPORATION AND SUBSIDIARY COMPANIES
FOOTNOTES TO FINANCIAL STATEMENTS
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2019 AND 2018
(unaudited)
(a) Included in the results of operations for 2019 are the following significant credits/(charges) which may not be indicative of ongoing operations
(in thousands):
Three Months Ended September 30, 2019
VITAS Roto-Rooter Corporate Consolidated
Service revenues and sales:
Medicare cap sequestration adjustment $ (859) $ - $ - $ (859)
Selling, general and administrative expenses:
Acquisition expense - (3,281) - (3,281)
Stock option expense - - (2,711) (2,711)
Long-term incentive compensation - - (1,677) (1,677)
Amortization of acquired and cancelled franchise agreements - (331) - (331)
Pretax impact on earnings (859) (3,612) (4,388) (8,859)
Excess tax benefits on stock compensation - - 8,792 8,792
Income tax benefit on the above 220 957 624 1,801
After-tax impact on earnings $ (639) $ (2,655) $ 5,028 $ 1,734
Nine Months Ended September 30, 2019
VITAS Roto-Rooter Corporate Consolidated
Service revenues and sales:
Medicare cap sequestration adjustment $ (3,063) $ - $ - $ (3,063)
Selling, general and administrative expenses:
Stock option expense - - (10,729) (10,729)
Long-term incentive compensation - - (4,552) (4,552)
Acquisition expense - (3,377) (120) (3,497)
Amortization of acquired and cancelled franchise agreements - (1,103) - (1,103)
Non cash ASC 842 (expenses)/benefit (656) (55) 163 (548)
Other operating expenses:
Litigation settlement (6,000) - - (6,000)
Impairment loss on transportation equipment - - (2,266) (2,266)
Pretax impact on earnings (9,719) (4,535) (17,504) (31,758)
Excess tax benefits on stock compensation - - 18,737 18,737
Income tax benefit on the above 2,474 1,202 3,085 6,761
After-tax impact on earnings $ (7,245) $ (3,333) $ 4,318 $ (6,260)
(b) Included in the results of operations for 2018 are the following significant credits/(charges) which may not be indicative of ongoing operations
(in thousands):
Three Months Ended September 30, 2018
VITAS Roto-Rooter Corporate Consolidated
Service revenues and sales:
Medicare cap sequestration adjustment $ (503) $ - $ - $ (503)
Selling, general and administrative expenses:
Stock option expense - - (2,055) (2,055)
Long-term incentive compensation - - (1,234) (1,234)
Acquisition expense (177) (177) - (354)
Pretax impact on earnings (680) (177) (3,289) (4,146)
Excess tax benefits on stock compensation - - 3,118 3,118
Income tax benefit on the above 172 47 602 821
After-tax impact on earnings $ (508) $ (130) $ 431 $ (207)
Nine Months Ended September 30, 2018
VITAS Roto-Rooter Corporate Consolidated
Service revenues and sales:
Medicare cap sequestration adjustment $ (1,040) $ - $ - $ (1,040)
Selling, general and administrative expenses:
Stock option expense - - (9,360) (9,360)
Long-term incentive compensation - - (4,376) (4,376)
Acquisition expense (177) (177) - (354)
Other operating expenses:
Litigation settlement 204 - - 204
Pretax impact on earnings (1,013) (177) (13,736) (14,926)
Excess tax benefits on stock compensation - - 18,618 18,618
Income tax benefit on the above 256 47 2,756 3,059
After-tax impact on earnings $ (757) $ (130) $ 7,638 $ 6,751
(c) VITAS has 12 large (greater than 450 ADC), 19 medium (greater than 200 but less than 450 ADC) and 17 small (less than 200 ADC) hospice programs. Of Vitas' 30 Medicare provider numbers, 24 provider numbers have a Medicare cap cushion of 5% or greater for the most recent twelve months, three provider numbers have a cap cushion between 0% and 5%, and three provider numbers have a Medicare cap liability.
Last updated: Oct 29, 2019